Jul 24, 2007 by Brian Orelli, PhDNo Pharma Love for ScheringA doubling of earnings, but no jump in stock price?
Jul 24, 2007 by Brian Orelli, PhDA Generic Roller CoasterStrong competition means Dr. Reddy's looks like it's down.
Jul 24, 2007 by Brian Orelli, PhDIs Amylin a Two-Hit Wonder?Two drugs, no profitability. At least not yet.
Jul 20, 2007 by Brian Orelli, PhDArena Keeps Burning the CashThe pipeline drugs hold promise, but it will be a while before the company shows a profit.
Jul 19, 2007 by Brian Orelli, PhDHead to the U.S. to Sue Your NeighborNovo Nordisk and Sanofi-Aventis fight over insulin-delivery systems.
Jul 18, 2007 by Brian Orelli, PhDPain-Free Payday for DURECTResults from a trial take it one step closer to possible approval for a local anesthetic.
Jul 17, 2007 by Brian Orelli, PhDAn Investor's Guide to the New PDUFASometimes Washington is more important than the laboratory.
Jul 17, 2007 by Brian Orelli, PhDA Fruitful CollaborationMonsanto and BASF team up to grow better plants.
Jul 16, 2007 by Brian Orelli, PhDBusiness as Usual for BarrThe maker of generic drugs gets sued twice in one week.
Jul 16, 2007 by Brian Orelli, PhDVentana Says No, We Can't TalkIt and Roche would be a good combination, but for now, this hostile takeover bid is stalled.
Jul 12, 2007 by Brian Orelli, PhDSupporting the Little CompanyTercica gets a partnership with Genentech.
Jul 11, 2007 by Brian Orelli, PhDEverybody Loves RNAiRoche is the latest firm to (over)pay for the hottest new drug technology.
Jul 11, 2007 by Brian Orelli, PhDIcy Hot Results From ChattemThe company sees a huge increase in sales, but can it last?
Jul 10, 2007 by Brian Orelli, PhDSometimes, the Same Is Good EnoughBristol-Myers Squibb's new drug doesn't work better, but it's easier to take.
Jul 6, 2007 by Brian Orelli, PhDPain-Free Phase 2 DataAnesiva's pain medication is moving up the clinical trial ladder.
